Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IGMSNASDAQ:STRONASDAQ:VYNENASDAQ:ZURA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIGMSIGM Biosciences$1.22-2.4%$1.21$0.92▼$22.50$72.93M0.61309,982 shs103,956 shsSTROSutro Biopharma$0.94+2.6%$0.79$0.52▼$5.17$79.76M1.771.10 million shs1.04 million shsVYNEVYNE Therapeutics$1.00-3.8%$1.49$0.96▼$4.30$15.21M1.76112,580 shs318,117 shsZURAZura Bio$1.00-2.0%$1.24$0.97▼$5.56$68.38M0.05409,539 shs565,550 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIGMSIGM Biosciences-2.40%-1.61%-7.58%-6.87%-87.23%STROSutro Biopharma+2.64%+4.96%+4.62%-41.35%-77.19%VYNEVYNE Therapeutics-3.85%-13.04%-30.07%-60.78%-61.24%ZURAZura Bio-1.96%-6.54%-27.01%-19.35%-81.79%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIGMSIGM Biosciences4.1015 of 5 stars3.02.00.04.62.03.31.3STROSutro Biopharma4.4427 of 5 stars4.13.00.04.72.81.70.6VYNEVYNE Therapeutics2.6641 of 5 stars3.53.00.00.03.31.70.6ZURAZura Bio2.6607 of 5 stars3.62.00.00.03.22.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIGMSIGM Biosciences 1.90Reduce$5.50350.82% UpsideSTROSutro Biopharma 2.13Hold$6.11547.49% UpsideVYNEVYNE Therapeutics 3.00Buy$6.25525.00% UpsideZURAZura Bio 3.13Buy$14.331,333.33% UpsideCurrent Analyst Ratings BreakdownLatest VYNE, STRO, IGMS, and ZURA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025STROSutro BiopharmaBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderperform ➝ Underperform$1.00 ➝ $0.805/9/2025ZURAZura BioOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$19.00 ➝ $17.004/29/2025STROSutro BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$2.00 ➝ $2.004/25/2025VYNEVYNE TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$5.75 ➝ $4.504/3/2025ZURAZura BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy4/3/2025ZURAZura BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$5.00 ➝ $3.003/26/2025ZURAZura BioOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$20.00 ➝ $19.003/26/2025ZURAZura BioGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.003/26/2025ZURAZura BioChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $10.003/17/2025STROSutro BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$12.00 ➝ $2.003/14/2025STROSutro BiopharmaPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$2.00(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIGMSIGM Biosciences$2.68M27.20N/AN/A$3.46 per share0.35STROSutro Biopharma$66.43M1.20N/AN/A$2.45 per share0.39VYNEVYNE Therapeutics$605K25.14N/AN/A$6.36 per share0.16ZURAZura BioN/AN/AN/AN/A$1.85 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIGMSIGM Biosciences-$246.42M-$3.27N/AN/AN/A-7,534.03%-155.42%-61.04%8/13/2025 (Estimated)STROSutro Biopharma-$106.79M-$2.98N/AN/AN/A-77.01%-101.89%-28.69%8/12/2025 (Estimated)VYNEVYNE Therapeutics-$28.45M-$0.99N/AN/AN/A-6,896.55%-43.73%-38.55%8/13/2025 (Estimated)ZURAZura Bio-$69.24M-$0.70N/AN/AN/AN/A-37.36%-29.81%8/12/2025 (Estimated)Latest VYNE, STRO, IGMS, and ZURA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025IGMSIGM Biosciences-$0.41-$0.86-$0.45-$0.86$4.25 million$0.50 million5/8/2025Q1 2025STROSutro Biopharma-$0.63-$0.91-$0.28-$0.91$11.61 million$17.40 million5/8/2025Q1 2025VYNEVYNE Therapeutics-$0.29-$0.20+$0.09-$0.20$0.05 million$0.20 million5/8/2025Q1 2025ZURAZura Bio-$0.17-$0.19-$0.02-$0.19N/AN/A3/25/2025Q4 2024ZURAZura Bio-$0.17-$0.08+$0.09-$0.08N/A$0.00 million3/13/2025Q4 2024STROSutro Biopharma-$0.86-$2.96-$2.10-$0.89$10.44 million$14.00 million3/6/2025Q4 2024IGMSIGM Biosciences-$0.74-$0.61+$0.13-$0.61$0.39 million$0.41 million3/6/2025Q4 2024VYNEVYNE Therapeutics-$0.31-$0.28+$0.03-$0.28$0.14 million$0.08 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIGMSIGM BiosciencesN/AN/AN/AN/AN/ASTROSutro BiopharmaN/AN/AN/AN/AN/AVYNEVYNE TherapeuticsN/AN/AN/AN/AN/AZURAZura BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIGMSIGM BiosciencesN/A5.225.22STROSutro BiopharmaN/A3.093.09VYNEVYNE TherapeuticsN/A5.815.81ZURAZura BioN/A10.3610.36Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIGMSIGM Biosciences42.79%STROSutro Biopharma96.99%VYNEVYNE Therapeutics83.78%ZURAZura Bio61.14%Insider OwnershipCompanyInsider OwnershipIGMSIGM Biosciences57.00%STROSutro Biopharma3.60%VYNEVYNE Therapeutics4.80%ZURAZura Bio14.23%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIGMSIGM Biosciences19059.78 million25.57 millionOptionableSTROSutro Biopharma24084.46 million77.59 millionOptionableVYNEVYNE Therapeutics3015.21 million14.04 millionNot OptionableZURAZura Bio368.38 million50.86 millionOptionableVYNE, STRO, IGMS, and ZURA HeadlinesRecent News About These CompaniesZura Bio Limited (NASDAQ:ZURA) Receives $14.33 Average Target Price from AnalystsMay 27 at 1:17 AM | americanbankingnews.comZura Bio Limited (NASDAQ:ZURA) Given Average Recommendation of "Buy" by BrokeragesMay 26 at 3:44 AM | marketbeat.comZura Bio shareholders approve board nominees and auditorMay 24, 2025 | investing.comHC Wainwright Issues Positive Estimate for Zura Bio EarningsMay 23, 2025 | marketbeat.comWhat is HC Wainwright's Forecast for Zura Bio Q2 Earnings?May 23, 2025 | americanbankingnews.comQ1 Earnings Estimate for Zura Bio Issued By HC WainwrightMay 22, 2025 | marketbeat.comZura Bio commences Phase II trial of tibulizumab for hidradenitis suppurativaMay 21, 2025 | msn.comWhat is HC Wainwright's Forecast for Zura Bio Q1 Earnings?May 21, 2025 | americanbankingnews.comZura Bio Launches Global Phase 2 TibuSHIELD Study to Evaluate Tibulizumab in Adults with Hidradenitis SuppurativaMay 20, 2025 | businesswire.comZura Bio Reports First Quarter 2025 Financial Results and Recent Corporate UpdatesMay 9, 2025 | standard-journal.comBoxer Capital Management LLC Makes New Investment in Zura Bio Limited (NASDAQ:ZURA)May 4, 2025 | marketbeat.comZura Bio (ZURA) Projected to Post Quarterly Earnings on ThursdayMay 3, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Buys Shares of 300,000 Zura Bio Limited (NASDAQ:ZURA)May 2, 2025 | marketbeat.comZura Bio Limited (NASDAQ:ZURA) Receives Average Recommendation of "Buy" from AnalystsMay 1, 2025 | marketbeat.comZura Bio Limited (NASDAQ:ZURA) Short Interest Down 51.8% in AprilApril 30, 2025 | marketbeat.comAfter losing 56% in the past year, Zura Bio Limited (NASDAQ:ZURA) institutional owners must be relieved by the recent gainApril 24, 2025 | finance.yahoo.comZura Bio price target lowered to $3 from $5 at H.C. WainwrightApril 4, 2025 | markets.businessinsider.comZura Bio (ZURA) Gets a Buy from GuggenheimMarch 31, 2025 | markets.businessinsider.comHopeful Week For Insiders Who Bought US$1.01m Of Zura Bio StockMarch 26, 2025 | finance.yahoo.comZura Bio Limited: 2024 Financial Results and Strategic ProgressMarch 26, 2025 | tipranks.comZura Bio Reports Full Year 2024 Financial Results and Recent Corporate UpdatesMarch 25, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesD-Wave Pushes Back on Short Seller Case With Strong EarningsBy Nathan Reiff | May 14, 2025View D-Wave Pushes Back on Short Seller Case With Strong EarningsPalantir’s Latest Deal Could Put a Freeze on Its Stock PriceBy Chris Markoch | May 12, 2025View Palantir’s Latest Deal Could Put a Freeze on Its Stock PriceIf the U.S.-China Trade Reset Holds, These 3 Stocks Could FlyBy Chris Markoch | May 16, 2025View If the U.S.-China Trade Reset Holds, These 3 Stocks Could FlyArcher Rebuts Short Seller, Points to Strong Q1 & Global MomentumBy Jeffrey Neal Johnson | May 22, 2025View Archer Rebuts Short Seller, Points to Strong Q1 & Global MomentumAfter Earnings Beats, These 3 Stocks Are on Analysts’ RadarsBy Leo Miller | May 20, 2025View After Earnings Beats, These 3 Stocks Are on Analysts’ RadarsVYNE, STRO, IGMS, and ZURA Company DescriptionsIGM Biosciences NASDAQ:IGMS$1.22 -0.03 (-2.40%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$1.18 -0.03 (-2.87%) As of 05:30 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.Sutro Biopharma NASDAQ:STRO$0.94 +0.02 (+2.64%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$0.94 -0.01 (-0.56%) As of 05/27/2025 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.VYNE Therapeutics NASDAQ:VYNE$1.00 -0.04 (-3.85%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$1.05 +0.05 (+4.70%) As of 05/27/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.Zura Bio NASDAQ:ZURA$1.00 -0.02 (-1.96%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$1.04 +0.04 (+4.00%) As of 06:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft's Outlook Brightens as Analysts Boost Bullish Ratings Palantir Scores First $1 Billion Contract; Is It Priced In? Tesla: Why Analysts Think It Could Jump Another 47% Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook 3 Dividend Stocks to Get You Through Tariff Volatility Apple Sinks After New 25% Tariff Announcement—What's The Bottom? MarketBeat Week in Review – 05/19 - 05/23 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.